Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer

Ahmad A. Tarhini, Imran Rafique, Theofanis Floros, Phu Tran, William E. Gooding, Liza C. Villaruz, Timothy F. Burns, David M. Friedland, Daniel P. Petro, Mariya Farooqui, Jose Gomez-Garcia, Autumn Gaither-Davis, Sanja Dacic, Athanassios Argiris, Mark A. Socinski, Laura P. Stabile, Jill M. Siegfried

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences